2024-03-29T12:04:51Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/96392022-10-14T10:07:57Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2088com_20.500.12105_2052com_20.500.12105_2053col_20.500.12105_16963col_20.500.12105_2089col_20.500.12105_2054
00925njm 22002777a 4500
dc
Portocarrero Nuñez, Julian Alexander
author
Gonzalez-Garcia, Juan
author
Berenguer, Juan
author
Gallego, María Jesús Vivancos
author
Loyarte, Jose Antonio Iribarren
author
Metola, Luis
author
Bernal, Enrique
author
Navarro, Gemma
author
Amo, Julia del
author
Jarrin-Vera, Inmaculada
author
2018-09
We assessed the effect of co-infection by hepatitis C virus (HCV) on immunological and virological response at 48 weeks from initiation of antiretroviral therapy (ART).We included patients from the Cohort of Spanish HIV Research Network (CoRIS) starting ART between January 2004 and November 2014, had at least 1 CD4 T-cell count and viral load measurements both in the previous 6 months and at 48 (±12) weeks from ART initiation, and HCV serology before ART initiation. We used linear regression for mean differences in CD4 T-cell count increase from ART initiation and logistic regression to estimate odds ratios for virological response.Of 12,239 patients by November 30, 2015, 5070 met inclusion criteria: 4382 (86.4%) HIV mono-infected and 688 (13.6%) HIV/HCV co-infected. Co-infected patients were more likely to have acquired HIV through injecting drugs use (57.4% vs. 1.1%), to be women, older, and Spanish, have a lower educational level, and having started ART with lower CD4 counts and acquired immunodeficiency syndrome. CD4 T-cell count increase at 48 weeks was 229.7 cell/μL in HIV-monoinfected and 161.9 cell/μL in HIV/HCV-coinfected patients. The percentages of patients achieving a virological response at 48 weeks were 87.0% and 78.3% in mono and coinfected patients, respectively. Multivariable analyses showed that at 48 weeks, coinfected patients increased 44.5 (95% confidence interval [CI]: 24.8-64.3) cells/μL less than monoinfected and had lower probability of virological response (odds ratio: 0.62; 95% CI: 0.44-0.88).HIV/HCV-coinfected patients have lower immunological and virological responses at 48 weeks from ART initiation than monoinfected patients.
Medicine (Baltimore) . 2018 Sep;97(38):e12238.
0025-7974
http://hdl.handle.net/20.500.12105/9639
30235668
10.1097/MD.0000000000012238
1536-5964
Medicine
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients